Where does the AstraZeneca–Bristol Myers deal stand on 30 Sep 2026?
Multiple choiceResolves 30 Sep 2026
Hunch
Formal merger agreement announced10%
Talks formally ended34%
No formal statement either way48%
Different partner or structure announced8%
Your forecast
Formal merger agreement announced
Talks formally ended
No formal statement either way
Different partner or structure announced
Resolved
Resolved: No formal statement either way
AstraZeneca's RNS feed from August to 30 September 2026 has no announcement about Bristol Myers Squibb and BMS filed no 8-K on it; the only denial, on 5 August, came from an unnamed source to Reuters, which is not a formal statement.
Resolved 30 Sep 2026
How this resolves
The market resolves on the most recent RNS position on londonstockexchange.com as at close on 30 September 2026. If that source has not published in time, astrazeneca.com or investegate.co.uk, with SEC filings from Bristol Myers Squibb accepted as a corroborating record of the same fact settle it.
The pattern behind it
2 of 5
Two of the last five public UK pharma megamerger episodes since 1998 produced an agreed or firm offer, and all five reached a definitive answer within six weeks. Only two of the five ended in a completed deal, and not the same two: Takeda closed on Shire, AbbVie signed and then terminated. The clock doing the forcing was the Takeover Code's, because in every case the UK company was the target, so a Panel deadline compelled a firm offer or a walk-away. AstraZeneca is the larger party this time and Bristol Myers is US-listed, so no put-up-or-shut-up clock automatically runs. The speed base rate travels only partly. The full record is the same five episodes, 1998 to 2022.
We looked for merger talks involving a UK-listed drugmaker that became public before any deal was signed. Since 1998 this has happened five times. All five ended within six weeks, either with a firm offer or with the talks dead. Two produced an agreed or firm offer, and three collapsed.
Some cookies are essential for Hunch to work properly. Others are optional—you decide whether to allow them. We don’t sell your personal data. Learn more and change your choices at any time in Cookie settings.